Research location
Mitaka
Tokyo, Japan
Advertisement
Research activity in Mitaka
Tokyo, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 51 trials and 54 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mitaka
51 linked trials · page 1 of 2A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)NCT06925750 · 2025-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)NCT06721156 · 2024-12-16 · 1 site observation
TERMINATED
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)NCT06664801 · 2024-11-14 · 1 site observation
COMPLETED
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004 · 2023-09-28 · 1 site observation
COMPLETED
Special Drug Use Surveillance of Entresto Tablets (Hypertension)NCT05976230 · 2023-09-04 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)NCT05818137 · 2023-05-10 · 1 site observation
COMPLETED
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)NCT05454410 · 2023-03-13 · 1 site observation
COMPLETED
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving DurvalumabNCT04884269 · 2021-08-11 · 1 site observation
COMPLETED
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesNCT04809220 · 2021-04-13 · 1 site observation
COMPLETED
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDNCT04717635 · 2021-03-30 · 1 site observation
COMPLETED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)NCT04221945 · 2020-05-12 · 1 site observation
COMPLETED
KW-3357 Study in Patients With Early Onset Severe PreeclampsiaNCT04182373 · 2019-11-19 · 1 site observation
COMPLETED
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)NCT04003636 · 2019-09-24 · 1 site observation
COMPLETED
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLCNCT03995875 · 2019-07-25 · 1 site observation
COMPLETED
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)NCT03867084 · 2019-05-28 · 1 site observation
COMPLETED
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesNCT03861039 · 2019-03-30 · 1 site observation
COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)NCT03713593 · 2018-12-31 · 1 site observation
COMPLETED
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · 2018-12-18 · 1 site observation
COMPLETED
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)NCT03615326 · 2018-10-05 · 1 site observation
COMPLETED
A Prospective Pilot Study (BIO|SELECT Pilot)NCT03337763 · 2017-11-07 · 1 site observation
COMPLETED
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)NCT03189719 · 2017-07-25 · 1 site observation
COMPLETED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30 · 1 site observation
COMPLETED
Tofogliflozin GLP-1 Analogue Combination TrialNCT02537834 · 2015-08-01 · 1 site observation
COMPLETED
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive DisorderNCT02389816 · 2015-04-10 · 1 site observation
COMPLETED
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma PatientsNCT02396316 · 2015-04-02 · 1 site observation
COMPLETED
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in JapanNCT02226822 · 2014-09-20 · 1 site observation
COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · 2014-09-12 · 1 site observation
COMPLETED
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in JapanNCT02042014 · 2014-01-22 · 1 site observation
COMPLETED
An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisNCT01885078 · 2013-06-27 · 1 site observation
COMPLETED
Azilsartan Circadian and Sleep PressureNCT01762501 · 2012-12-01 · 3 site observations
COMPLETED
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisNCT01850966 · 2012-09-12 · 1 site observation
COMPLETED
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation StudyNCT01469169 · 2012-06-19 · 1 site observation
COMPLETED
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)NCT01463891 · 2011-07-19 · 1 site observation
COMPLETED
Intravitreal Aflibercept Injection in Vision Impairment Due to DMENCT01331681 · 2011-05-09 · 1 site observation
COMPLETED
Efficacy Study of Water Drinking on PKD Progression.NCT01348035 · 2011-04-01 · 1 site observation
COMPLETED
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes MellitusNCT01294436 · 2011-02-01 · 1 site observation
COMPLETED
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event AssessmentsNCT01173939 · 2010-07-01 · 2 site observations
TERMINATED
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-NCT01129596 · 2010-06-10 · 1 site observation
COMPLETED
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)NCT01117987 · 2010-04-01 · 1 site observation
TERMINATED
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)NCT00890279 · 2009-07-01 · 1 site observation
UNKNOWN
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial HypertensionNCT00863681 · 2009-03-12 · 1 site observation
COMPLETED
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.NCT00855465 · 2009-02-23 · 1 site observation
COMPLETED
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)NCT00810693 · 2008-12-17 · 1 site observation
COMPLETED
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate CancerNCT00626548 · 2008-01-01 · 1 site observation
TERMINATED
CCB Safety Study in Treatment of Hypertension of ADPKDNCT00541853 · 2007-12-01 · 1 site observation
UNKNOWN
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone MetastasesNCT00554229 · 2007-11-01 · 1 site observation
COMPLETED
Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic RetinopathyNCT02464800 · 2007-04-01 · 1 site observation
COMPLETED
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast CancerNCT00143390 · 2005-04-01 · 1 site observation
COMPLETED
Macular Retinoschisis and Detachment Associated With Glaucomatous Optic NeuropathyNCT01862627 · 2004-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.